Lewy body pathology in fetal grafts
- PMID: 20146690
- DOI: 10.1111/j.1749-6632.2009.05229.x
Lewy body pathology in fetal grafts
Abstract
Although fetal nigral transplants have been shown to survive grafting into the striatum, increased [(18)F]6-fluroro-L-3,4-dihydroxyphenylalanine ((18)F-DOPA) uptake and improved motor function in open-label assessments have failed to establish any clinical benefits in double-blind, sham-controlled studies. To understand morphological and neurochemical alterations of grafted neurons, we performed postmortem analyses on six Parkinson's disease (PD) patients who had received fetal tissue transplantation 18-19 months, 4 years, and 14 years previously. These studies revealed robust neuronal survival with normal dopaminergic phenotypes in 18-month-old grafts and decreased dopamine transporter and increased cytoplasmic alpha-synuclein in 4-year-old grafts. We also found a decline of both dopamine transporter and tyrosine hydroxylase and the formation of Lewy body-like inclusions in 14-year-old grafts, which stained positive for alpha-synuclein and ubiquitin proteins. These pathological changes suggest that PD is an ongoing process that affects grafted cells in the striatum in a manner similar to how resident dopamine neurons are affected in the substantia nigra.
Similar articles
-
Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease.Mov Disord. 1998 May;13(3):383-93. doi: 10.1002/mds.870130303. Mov Disord. 1998. PMID: 9613726
-
Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Brain. 2005 Nov;128(Pt 11):2654-64. doi: 10.1093/brain/awh584. Epub 2005 Jul 6. Brain. 2005. PMID: 16000336
-
Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease.Mov Disord. 2010 Jun 15;25(8):1091-6. doi: 10.1002/mds.23012. Mov Disord. 2010. PMID: 20198645
-
Neuropathology of fetal nigral grafts in patients with Parkinson's disease.Mov Disord. 1998;13 Suppl 1:88-95. Mov Disord. 1998. PMID: 9613724 Review. No abstract available.
-
Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.Brain Res Rev. 2006 Sep;52(2):244-56. doi: 10.1016/j.brainresrev.2006.03.001. Epub 2006 Apr 27. Brain Res Rev. 2006. PMID: 16644019 Review.
Cited by
-
Cell-based therapies for Parkinson disease—past insights and future potential.Nat Rev Neurol. 2015 Sep;11(9):492-503. doi: 10.1038/nrneurol.2015.123. Epub 2015 Aug 4. Nat Rev Neurol. 2015. PMID: 26240036 Review.
-
How strong is the evidence that Parkinson's disease is a prion disorder?Curr Opin Neurol. 2016 Aug;29(4):459-66. doi: 10.1097/WCO.0000000000000349. Curr Opin Neurol. 2016. PMID: 27257944 Free PMC article. Review.
-
α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.J Clin Invest. 2011 Feb;121(2):715-25. doi: 10.1172/JCI43366. Epub 2011 Jan 18. J Clin Invest. 2011. PMID: 21245577 Free PMC article.
-
Induced pluripotent stem cell-related approaches to generate dopaminergic neurons for Parkinson's disease.Neural Regen Res. 2025 Nov 1;20(11):3193-3206. doi: 10.4103/NRR.NRR-D-24-00771. Epub 2024 Dec 7. Neural Regen Res. 2025. PMID: 39665833 Free PMC article.
-
Reverse engineering Lewy bodies: how far have we come and how far can we go?Nat Rev Neurosci. 2021 Feb;22(2):111-131. doi: 10.1038/s41583-020-00416-6. Epub 2021 Jan 11. Nat Rev Neurosci. 2021. PMID: 33432241 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources